Owl Creek Wealth Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Owl Creek Wealth Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.84K	Buy	+145	New	+$3.6K	﹤0.01%	1025

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Owl Creek Wealth Partners's RARE Position: Q2 2026 in Review

Owl Creek Wealth Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 145 shares worth $4.84K. The stake represents ﹤0.01% of the portfolio and ranks #1025 among its holdings.

287 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Owl Creek Wealth Partners held 145 shares of Ultragenyx Pharmaceutical worth $4.84K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Owl Creek Wealth Partners position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1025 holding.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.